Schoninger SF, Blain SW. The Ongoing Search for Biomarkers of CDK4/6 Inhibitor Responsiveness in Breast Cancer. Mol Cancer Ther. 2020;19(1):3–12.
Preusser M, De Mattos-Arruda L, Thill M, et al. CDK4/6 inhibitors in the treatment of patients with breast cancer: summary of a multidisciplinary round-table discussion [published correction appears in ESMO Open. 2019 Mar 11;4(2):e000368corr1]. ESMO Open. 2018;3(5):e000368.
Niu Y, Xu J, Sun T. Cyclin-Dependent Kinases 4/6 Inhibitors in Breast Cancer: Current Status, Resistance, and Combination Strategies. J Cancer. 2019;10(22):5504–5517. Published 2019 Aug 29. doi:10.7150/jca.32628
Yu Q, Geng Y, Sicinski P. Specific protection against breast cancers by cyclin D1 ablation. Nature. 2001;411, 1017–1021.
Im SA, Lu YS, Bardia A, et al. Overall survival with ribociclib plus endocrine therapy in breast cancer. N Engl J Med. 2019; 381:307-316.
Li M, Xiao A, Floyd D, et al. CDK4/6 inhibition is more active against the glioblastoma proneural subtype. Oncotarget. 2017;8(33):55319–55331.
van Caloen G, Machiels JP. Potential role of cyclin-dependent kinase 4/6 inhibitors in the treatment of squamous cell carcinoma of the head and neck. Curr Opin Oncol. 2019;31(3):122–130.
Zhang YX, Sicinska E, Czaplinski JT, et al. Antiproliferative effects of CDK4/6 inhibition in CDK4-amplified human liposarcoma in vitro and in vivo. Mol Cancer Ther. 2014;13(9):2184–2193.
Chaturvedi NK, Hatch ND, Sutton GL, et al. A novel approach to eliminate therapy-resistant mantle cell lymphoma: synergistic effects of Vorinostat with Palbociclib. Leuk Lymphoma. 2019;60(5):1214–1223.
Kollmann K, Briand C, Bellutti F, et al. The interplay of CDK4 and CDK6 in melanoma. Oncotarget. 2019;10(14):1346–1359.
Goldstein AM, Chidambaram A, Halpern A, et al. Rarity of CDK4 germline mutations in familial melanoma. Melanoma Res. 2002;12(1):51–55.
Rihani A, Vandesompele J, Speleman F, et al. Inhibition of CDK4/6 as a novel therapeutic option for neuroblastoma. Cancer Cell Int. 2015;15:76.
Geoerger B, Bourdeaut F, DuBois SG, et al. A Phase I Study of the CDK4/6 Inhibitor Ribociclib (LEE011) in Pediatric Patients with Malignant Rhabdoid Tumors, Neuroblastoma, and Other Solid Tumors. Clin Cancer Res. 2017;23(10):2433–2441.
Pacheco J, Schenk E. CDK4/6 inhibition alone and in combination for non-small cell lung cancer. Oncotarget. 2019;10(6):618–619.
Franco J, Witkiewicz AK, Knudsen ES. CDK4/6 inhibitors have potent activity in combination with pathway selective therapeutic agents in models of pancreatic cancer. Oncotarget. 2014;5(15):6512–6525.
Based on results from the phase 2 CADENZA trial, the FDA has approved pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms.
Based on results from the phase 2 CADENZA trial, the FDA has approved pivekimab sunirine for adult patients with blastic plasmacytoid dendritic cell neoplasms.
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Updated results from the phase 3 CROWN study demonstrate that lorlatinib sustains long-term benefit in treatment-naïve patients with advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
Results from a multicenter phase 2 study demonstrated that neoadjuvant lorlatinib induced high pathological response and enabled substantial conversion to surgery in advanced ALK-positive non-small cell lung cancer.
According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.
According to results from a phase 3 trial, trastuzumab rezetecan significantly improved survival and response in chemotherapy-refractory HER2-positive advanced colorectal cancer.
Results from the 2 CHRONO trial demonstrated that delaying interval surgery until after 6 cycles of neoadjuvant chemotherapy did not significantly improve survival in advanced ovarian cancer.
Results from the 2 CHRONO trial demonstrated that delaying interval surgery until after 6 cycles of neoadjuvant chemotherapy did not significantly improve survival in advanced ovarian cancer.
Final subgroup analyses from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel significantly improved overall survival in platinum-resistant ovarian cancer.
Final subgroup analyses from the phase 3 ROSELLA trial demonstrated that relacorilant plus nab-paclitaxel significantly improved overall survival in platinum-resistant ovarian cancer.
Results from the phase 2 MIROVA/AGO-OVAR 2.34 trial demonstrated that carboplatin plus mirvetuximab soravtansine did not improve progression-free survival in patients with platinum-eligible relapsed ovarian cancer with high FRα expression.
Results from the phase 2 MIROVA/AGO-OVAR 2.34 trial demonstrated that carboplatin plus mirvetuximab soravtansine did not improve progression-free survival in patients with platinum-eligible relapsed ovarian cancer with high FRα expression.
Updated results from the phase 3 RUBY trial showed durable PFS benefit with dostarlimab plus chemotherapy in dMMR/MSI-H advanced or recurrent endometrial cancer, with modeling analyses suggesting potential long-term cure in a substantial...
Updated results from the phase 3 RUBY trial showed durable PFS benefit with dostarlimab plus chemotherapy in dMMR/MSI-H advanced or recurrent endometrial cancer, with modeling analyses suggesting potential long-term cure in a substantial...
Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Interim results from cohort 1 of the phase 2 LEGEND study demonstrated that detalimogene voraplasmid showed encouraging efficacy and safety in Bacillus Calmette-Guérin (BCG)-unresponsive non-muscle invasive bladder cancer.
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
Long-term results from a phase 3 trial demonstrated that extended pelvic lymph node dissection did not improve survival outcomes compared with limited pelvic lymph node dissection in patients with intermediate- or high-risk prostate cancer...
